1. Financial Results Approval

The Board approved the Unaudited Standalone and Consolidated Financial Results for the quarter and half-year ended September 30, 2026. The results were reviewed by the statutory auditors, M/s. S R Batliboi & Associates, who issued a Limited Review Report dated November 06, 2026, in accordance with Regulation 33 of the Listing Regulations.

2. Rights Issue Funds Utilization

The Board approved the Statement of Deviation(s) and Variation(s) and the Monitoring Agency Report regarding the utilization of funds raised through the Rights Issue by the Company in December 2025.

3. Management Changes

  • Cessation of Mr. N. Shankar: The Board noted the superannuation of Mr. N. Shankar, Chief Financial Officer and Key Managerial Personnel, effective from the close of business hours on December 31, 2026.
  • Appointment of Mr. Ankur Gupta: The Board approved the appointment of Mr. Ankur Gupta as Chief Financial Officer and Key Managerial Personnel, effective January 01, 2027, based on recommendations of the Audit Committee and Nomination and Remuneration Committee.
  • Appointment of Mr. Indranil Chowdhury: The Board approved the appointment of Mr. Indranil Chowdhury as Head - Field Sales (B2C) and Senior Management Personnel, effective November 06, 2026.

4. Board Meeting Details

The meeting commenced at 09:30 a.m. and concluded at 11:00 a.m. on November 06, 2026.

Management Profiles

Mr. Ankur Gupta (Incoming CFO)

  • Associate Vice President - Finance at Coromandel International Limited (Holding Company)
  • Holds a master's degree in commerce from Rajasthan University, Jaipur
  • Member of The Institute of Chartered Accountants of India
  • Over 22 years of progressive corporate finance experience across Agrochemicals, FMCG, Metals, and Building Products
  • Previously held leadership roles at Vedanta Resources, Britannia Industries Ltd, HSIL, and Guiltfree Industries Ltd (RPSG Group)

Mr. Indranil Chowdhury (Head - Field Sales)

  • Holds a B.Sc. (Agriculture) Honours degree and Post Graduate Diploma in Management (PGDM) from MANAGE, Hyderabad
  • Commenced career as Management Trainee with UPL, subsequently worked with ICICI Bank
  • Joined Coromandel International Limited in 2008 as Product Manager
  • Progressed through various roles including Zonal Manager and Head - Sales (Formulation)
  • Extensive experience in strategic sales, marketing, and business development in Crop Protection Chemicals

Financial Results Overview (₹ in lakhs)

Standalone Performance (Quarter Ended September 30, 2026)

  • Revenue from operations: ₹45,694
  • Total income: ₹45,690
  • Total expenses: ₹43,300
  • Profit before tax: ₹2,390
  • Net profit after tax: ₹1,789
  • Earnings per share (Basic): ₹0.76
  • Earnings per share (Diluted): ₹0.76

Consolidated Performance (Quarter Ended September 30, 2026)

  • Revenue from operations: ₹51,530
  • Total income: ₹51,530
  • Total expenses: ₹47,522
  • Profit before tax: ₹4,008
  • Net profit after tax: ₹2,875
  • Earnings per share (Basic): ₹1.23
  • Earnings per share (Diluted): ₹1.23

Comparative Half-Year Performance (September 30, 2026 vs September 30, 2025)

Standalone:

  • Half-year ended September 2026: Net profit of ₹3,972
  • Half-year ended September 2025: Net profit of ₹2,760

Consolidated:

  • Half-year ended September 2026: Net profit of ₹4,673
  • Half-year ended September 2025: Net profit of ₹4,024

Auditor's Review

S.R. Batliboi & Associates LLP conducted a limited review of the financial results and issued unmodified reports for both standalone and consolidated results. The review was conducted in accordance with Standard on Review Engagements (SRE) 2410 issued by the Institute of Chartered Accountants of India.

The consolidated results include the following entities:

  • Holding Company: NACL Industries Limited
  • Subsidiaries: NACL Spec-Chem Limited, NACL Multichem Private Limited, NACL Agri-Solutions Private Limited, LR Research Laboratories Private Limited, Nagarjuna Agrichem (Australia) Pty Limited, NACL Industries (Nigeria) Limited
  • Associate: Nasense Labs Private Limited (till August 10, 2026)

Additional Information

  • The Company completed a rights issue in December 2025 of 32,501,851 equity shares at ₹76.7 per share (including premium of ₹75.7), aggregating ₹24,771 lakhs (net of issue expenses of ₹158 lakhs)
  • Funds were utilized for debt repayment (₹18,700 lakhs) and general corporate purposes (₹6,071 lakhs)
  • Unutilized amount of ₹1,597 lakhs is deposited in earmarked bank account
  • The Company/Group is primarily engaged in farm inputs business